Due to author error, a correction has been issued for the above referenced article. The following sentence inaccurately spells out suPAR. The text should have read “soluble urokinase-type plasminogen activator receptor” instead of “serum urine–type plasminogen activator receptor”. The authors regret any confusion this may have caused to readers. “Current candidates for the recurrent FSGS factor, reviewed recently (44), include cardiotrophin like cytokine factor 1 (45), apoA1b (an isoform of ApoA1) (46), anti-CD40 antibody (47), and serum urine–type plasminogen activator receptor (suPAR) (48).”.
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine